Stockreport

Alto Neuroscience Reports Topline Data from Phase 2 Proof-of-Concept Study of ALTO-101 and Highlights Pipeline Advancements [Yahoo! Finance]

Alto Neuroscience, Inc.  (ANRO) 
PDF — Alto has developed a modified-release, once-daily oral formulation of ALTO-101; the Company plans to explore partnering opportunities for this formulation — — Devel [Read more]